Golimumab in Rheumatoid Arthritis Participants With an Inadequate Response to Etanercept (ENBREL) or Adalimumab (HUMIRA)
Status:
Completed
Trial end date:
2013-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of switching rheumatoid
arthritis (RA) participants who have an inadequate response to their current treatment with
either etanercept + methotrexate or adalimumab + methotrexate to treatment with golimumab 50
milligram (mg) subcutaneous (SC) injection (a needle inserted under the skin in the back of
upper arm, upper thigh or stomach area) every 4 weeks + methotrexate. This study is also
designed to evaluate the benefit and safety of switching participants from treatment with
golimumab 50 mg subcutaneous injection every 4 weeks + methotrexate to golimumab 2 milligram
per kilogram (mg/kg) intravenous every 8 weeks + methotrexate, for those who do not achieve a
marked improvement of their RA at Week 16.